DocumentsDate added
Research article
Reyadh Jassim Abbas1,*,May Al- Sabbagh1, Dr Hassan Mohammed Abbas Altemmi2, Dr Monewer3
Affiliation:-
1Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi
2Ph.D Clinical Pharmacy, Medical City Baghdad, Baghdad Iraq, 3MSC Oncology Medical City Baghdad, Iraq
The name of the department(s) and institution(s) to which the work should be attributed:
1Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi
Address reprint requests to
Reyadh Jassim Abbas
Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad Iraqi
Article citation:
Abbas RJ, Sabbagh-Al M, Altemmi Abaas HM, Monewer. The possible protective effect of melatonin in Iraqi breast cancer patients taking chemotherapy. J Pharm Biomed Sci. 2014; 04(11):1001-1006. Available at www.jpbms.info
ABSTRACT
Breast cancer is the most common cancer that lead to death in the world. The most common type of breast cancer is ductal carcinoma. Chemotherapy that used in the treatment of breast cancer is associated with adverse effects like cardio toxicity, especially with doxorubicin use, due to increase free radical formation like reactive oxygen species. To evaluate the protective effect of melatonin in Iraq breast cancer taking chemotherapy, 40 volunteers, 10 normal subjects served as control, 30 volunteers were divided into two groups randomly first 10 patient named group A taking only chemotherapy without melatonin. The second 20 patient named group B taking melatonin + chemotherapy. In the current study, we measured serum malondialdehyde (MDA), liver function test (ALT, AST and TSB) and cardiac enzyme (CPK and LDH). The results showed that chemo therapy increase serum MDA, AIT, AST, CPK, LDH and reduction in serum TSB. Patients who taking extra supplement with melatonin (group B) showed normalized of these biochemical parameters. Melatonin has a role in protecting against toxicity that produced by chemotherapy.
KEYWORDS: Breast cancer; Chemotherapy; melatonin.
REFERENCES
1.American cancer society . Breast cancer . Fact and Figure 2009. American cancer society, Atlanta, GA2009.
2.Iraq cancer registry, 2010,p28.
3.Wood, WC et at. Malignant tumor of breast in ;devitant,Hellman editor.Cancer principle and practice of oncology 7th edition , Philadelphia Pa. Lippincott william and Wilkins, pp77-1415.
4.Chu, E et al . Cancer chemotherapy.In; Katzung BG,editor. Basic and clinical pharmacology, 9th edition . Mc Graw-Hill, pp: 898-930.
5.Stefulj J et al. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res. 2001;30:243–247.
6.Ackermann K et al. Melatonin synthesis in the human pineal gland .BMC neuroscience. 2007; 8supp1:p2.
7.Pieri C. Melatonin peroxyl radical scavenger more effective than vit. E Life sci. 55(15): PL 271-6.
8.Reitman and frankel. As cited by Bio Merieux kit (france). Am J Clin Path.1957;28:56 .
9.Tietz N.W. text book of clinical chemistry 3rd ed. (1999):1133-1137.
10.Buege, JA, Austa SD. Method enzymol. 1978;51:302-310.
11.Sharhar S. et al. Antioxidant intake and status, and oxidative stress in relation to breast cancer risk: A case-control study. Asian Pac. J. Cancer Prev. 2008;9:343–349.
12.Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996;313:17-29.
13.A.Nath et al. Elevated lipid peroxidation in breast cancer patients, Journal of pharmacy and biological sciences (JPBS),2001;9(4):17-21.
14.Shaoyu Zhou,et al. Doxorubicin–induce persistent oxidative stress to cardiac myocytes.2001;121:(3):151-157.
15.Ganiyu Oboh et al . Cyclophosphamide- induced oxidative stress in brain. Experimental and Toxicologic Pathology.2014;66(8):351-406.
16.Satoshi Numazawa et al. Possible Involvement of Oxidative Stress in 5-Fluorouracil-Mediated myelosuppression in mice. Basic & Clinical Pharmacology & Toxicology.2011;108(1):40–45.
17.Qi W, Reiter RJ, Tan DX, et al. Inhibitory effects of melatonin on ferric nitrilotriacetate-induced lipid peroxidation and oxidative DNAdamage in the rat kidney. Toxicology.1999;139:81–91.
18.Bateman JR, et al. 5-Fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer. 1971;28:907-913.6
19.Paul D. King et al.Hepatotoxicity of Chemotherapy, The Oncologist.2001;6:162-176.p163.
20.Meredith MJ, Reed DJ. Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by Adriamycin and 1,3 chloroethyl-nitrosurea (BCNU). Biochem Pharmacol 1983;32:1383-1388.
21.Deepa PR, Varalakshmi P. Protective effect of low molecular weight heparin on oxidative injury and cellular abnormalities in adriamycin-induced cardiac and hepatic toxicity. Chemico-Biological Interactions. 2003;146:201-210.
22.Dr. Mustafa Ghazi Alabbassi. Melatonin Ameliorates Hepatic Damage Induced by Cyclophosphamide in rat.
23.Bahir Abdul Razzaq Mshemish et al . Effect of Silymarin against CAF protocol Hepatotoxicity, AJPS, 2011, Vol. 9, No.1.
24.Khalid A Al-Khazragi FRCP. Studying the Effect of Silymarin Against Hepatotoxicity Induced by CAF Protocol in Breast Cancer Women. Iraqi Medical Journal , Volume 56, Number 2, December 2010, ISSN 0304-4564.
25.Kamal Adel Amin,et al . Impact of Breast Cancer and Combination Chemotherapy on Oxidative Stress, Hepatic and Cardiac Markers, Sep 2012:15(3);306-312.
26.Ayça Bilginoğlu, M.D et al. Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats. Arch Turk Soc Cardiol 2014; 42(3):265-273.
27.Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. http://www.nlm.nih.gov. Drug Saf. 2000 Apr;22(4):263-170.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Abbas RJ, Sabbagh-Al M, Altemmi Abaas HM, Monewer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Neelam Sharma1,*, Anshul Jhanwar2
Affiliation:-
1Assistant Professor, Department of Obstetrics & Gynecology, Jhalawar medical college, Jhalawar, Rajasthan, India
2Assistant Professor, Department of Pharmacology, Jhalawar medical college, Jhalawar, Rajasthan, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Obstetrics & Gynecology, J.L.N. medical college, Ajmer, Rajasthan, India
Address reprint requests to
Dr. Anshul Jhanwar.
III/2,Doctor’s residence, Medical College Campus, Jhalawar, Rajasthan, India (Pin-326001)
Article citation:
Sharma N, Jhanwar A. To study the effect of Mifepristone-Misoprostol combination for first trimester abortion in cases with previously scarred uterus. J Pharm Biomed Sci 2014; 04(08):930-935. Available at www.jpbms.info
ABSTRACT
Introduction: In India to deal with unwanted pregnancy in the scarred uterus is thorny situation, since the caesarian section rate is increasing. Although most widely used method for terminating pregnancy is dilatation and evacuation but it increases morbidity and mortality by causing uterine perforation, serious hemorrhage and shock. Therefore medical abortion offers an advantageous alternative to surgical abortion.
Material and methods: Total one hundred and fifty patients were selected for the present prospective study and were divided randomly into two equal groups after fulfilling the inclusion and exclusion criteria. Both groups were given 200 mg Mifepristone followed by 800 µg Misoprostol after 48 hours. Group 1 consist of patients with previously scarred uterus. Group 2 consisted of patients with previously non-scarred uterus.
Results: Mean period of gestation in group 1 was 43.48 days and in group 2 was 43.81 days. Mean gravidity in group 1 was 3.24 and in group 2 was 3.17.Mean parity in group 1 was 2.2 while in group 2 was 2.14.Efficacy of procedure which was determined by the number of complete abortions in the group (92% in group 1 and 93.3% in group2.Minor side effects were seen in 21 % patients of group 1 as compared to 28% in group 2.
Conclusion: Both the groups who underwent medical abortion with mifepristone-misoprostol combination were found to be comparable in terms of efficacy, safety and acceptability for termination of pregnancy of gestational age upto 49 days.
KEYWORDS: Mifepristone, Misoprostol, Scarred uterus, Lower segment cesarean section.
REFERENCES
1.Norman JE et al. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 1991; 338:1233-1236.
2.Abraham Debby et al. Mid trimester abortion in patients with a previous uterine scar. European Journal of Obst & Gyne 2003.
3.Maitre SC,Bouchard P,Spitz IM .Medical termination of pregnancy.N Engl.J Med 2000;342:946-56.
4.Wu Y,Medical progress in China-Family planning.Natl Med J China 1995;75(12):749-75.
5.Creinin MD. Medical abortion regimens. Historical contest and overview. Am J Obstet & Gynecol 2000; 183:53-59.
6.Belfort P,Pinotti JA,Eskes Tkab.Fertility,sterility and contraception. Caterton Hall, Carnforth, UK: The Parthenon Publishing Group.1989; 28-31.
7.Bygdeman M. Termination of pregnancy upto 8 or 9 weeks-Modern methods of inducing abortion. Black-well science:Oxford;1995:39-53
8.Sun H,Wu S,Xu H et. Al.The potential of Ru 486 for medical termination of pregnancy: An acceptability and feasibility study. J Repro Med (China). 1995; 4(3):749-75.
9.Coyaji K,Etul B,Krishna U,Otiv S, Ambardekar S,Bopardikar A: Mifepristone abortion outside the urban research hospital setting in India.Lancet,2001;357:120-22.
10.Brogden RN, Goa KL, Faulds D. Mifepristone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1993; 45:384-409.
11.Renee M, Hart S. Mifepristone: Annuals of pharmacotherapy 2001;35:707-15.
12.Robbins A,Spitz IM. Mifepristone clinical pharmacology. Clin Obstet Gynecol 1996;39:436-50.
13.Berghella V,Airoldi J. Misoprostol for first trimester pregnancy termination in women with prior cesarean;a systemic review. BJOG;May 2009.
14.Muhammad Fawzy. Mid trimester abortion using vaginal misoprostol for women with 3 or more prior cesarean deliveries. JJOG 2010 March.
15.Premila W,Prabath T. Factors affecting outcome of early medical abortion: A review of 4132 consecutive cases; BJOG: Nov 2002;109:1281-89.
16.J Xu, Chen H. Termination of early pregnancy in scarred uterus with mifepristone and misoprostol. IJOG.72 (2001):245-51.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patients and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclosure forms provided by the authors are available with the full text of this article at jpbms.info
Copyright © 2014 Sharma N, Jhanwar A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.